Home » Politics » Sen. Warren leads Biogen’s Alzheimer drug Medicare inquiry
Sen. Warren leads Biogen’s Alzheimer drug Medicare inquiry
FDA approves Biogen’s Alzheimer’s medication: How to invest
T3 Trading chief strategist Scott Redler gives his market outlook on biotech investing.
Sen. Elizabeth Warren, D-Mass., is leading an effort to examine the Food and Drug Administration's (FDA's) recent approval of a drug to treat Alzheimer’s disease and its impact on Medicare.
The FDA on June 7 approved the drug called Aduhelm — the first FDA-approved medication to treat Alzheimer's — produced by Cambridge-based biotechnology company Biogen.
BIOGEN'S STOCK SOARS AS ALZHEIMER'S DRUG COST REVEALED FOLLOWING FDA APPROVAL
Warren and Sen. Bill Cassidy, D-Md., are concerned that the drug could "command" an estimated "$37 billion we currently spend on Medicare Part B and the $90 billion we currently spend on Medicare Part D," according to a Thursday letter addressed to Senate Finance Committee Chairman Ron Wyden, D-Ore., and Ranking Member Mike Crapo, R-Idaho.
"This level of potential new spending, particularly for just one product with limited evidence of clinical efficacy thus far, tests the program’s resilience," the senators wrote.